Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
APGE 
Apogee Therapeutics, Inc. Common Stock (APGE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: APGE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $96.55
1 Year Target Price $96.55
| 9 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 152.17% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.30B USD | Price to earnings Ratio - | 1Y Target Price 96.55 |
Price to earnings Ratio - | 1Y Target Price 96.55 | ||
Volume (30-day avg) 9 | Beta 1.52 | 52 Weeks Range 26.20 - 64.87 | Updated Date 11/12/2025 |
52 Weeks Range 26.20 - 64.87 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.38 |
Earnings Date
Report Date 2025-11-18 | When - | Estimate -0.61 | Actual -1.11 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.26% | Return on Equity (TTM) -38.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3784005617 | Price to Sales(TTM) - |
Enterprise Value 3784005617 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 54833587 | Shares Floating 46577999 |
Shares Outstanding 54833587 | Shares Floating 46577999 | ||
Percent Insiders 6.59 | Percent Institutions 114.48 |
Upturn AI SWOT
Apogee Therapeutics, Inc. Common Stock
Company Overview
History and Background
Apogee Therapeutics, Inc. is a biotechnology company focused on developing novel biologics for the treatment of inflammatory and immunological diseases. Founded in 2022, it leverages innovative antibody engineering to create differentiated therapeutic candidates.
Core Business Areas
- Biologics Development: Focused on creating novel biologics to address unmet needs in inflammatory and immunological diseases.
- Antibody Engineering: Utilizes innovative antibody engineering platforms to design and develop differentiated therapeutic candidates.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
Leadership and Structure
The company is led by a team of experienced biotechnology executives. The organizational structure consists of research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- APG777: A novel monoclonal antibody targeting IL-23 for the treatment of inflammatory bowel disease (IBD). Currently in clinical development. Competitors include drugs from companies such as Johnson & Johnson and AbbVie that target IL-23. Market share data is not yet available as it's in trials
- APG808: A novel monoclonal antibody targeting IL-4/IL-13 for the treatment of atopic dermatitis and asthma. Currently in clinical development. Competitors include Dupixent by Sanofi and Regeneron. Market share data is not yet available as it's in trials
Market Dynamics
Industry Overview
The biotechnology industry is experiencing significant growth, driven by advancements in genomics, proteomics, and antibody engineering. Demand for novel therapeutics for inflammatory and immunological diseases is high.
Positioning
Apogee Therapeutics, Inc. is positioned as an innovator in biologics development, focusing on differentiated antibody engineering and clinical execution. Their competitive advantage lies in their novel targets and potentially improved efficacy/safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The total addressable market for inflammatory and immunological disease therapeutics is estimated to be over $100 billion globally. Apogee is positioning itself to capture a significant share of this market with its pipeline of novel biologics.
Upturn SWOT Analysis
Strengths
- Novel antibody engineering platform
- Experienced leadership team
- Strong pipeline of therapeutic candidates
- Focus on high-value therapeutic areas
Weaknesses
- Early-stage company with limited commercialized products
- Reliance on clinical trial success
- Competition from established pharmaceutical companies
- Limited financial resources compared to larger competitors
Opportunities
- Partnering with larger pharmaceutical companies
- Expanding pipeline through internal development and acquisitions
- Addressing unmet medical needs in inflammatory and immunological diseases
- Potential for breakthrough therapies with superior efficacy and safety
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- SNY
- REGN
Competitive Landscape
Apogee Therapeutics competes with established pharmaceutical companies and other biotechnology firms in the inflammatory and immunological disease space. The competitive landscape is intense, requiring differentiated products and strong clinical execution.
Growth Trajectory and Initiatives
Historical Growth: Limited operating history; growth driven by pipeline advancement.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates project significant revenue growth in the coming years if key products are approved.
Recent Initiatives: Focus on advancing APG777 and APG808 through clinical trials, expanding research and development capabilities, and securing strategic partnerships.
Summary
Apogee Therapeutics is an early-stage biotechnology company with a promising pipeline of novel biologics. The company is focused on developing differentiated therapies for inflammatory and immunological diseases. Success hinges on clinical trial outcomes and navigating the competitive landscape. Apogee needs to secure partnerships and manage cash carefully.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share are rough estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Apogee Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2023-07-14 | CEO & Director Dr. Michael Thomas Henderson M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 196 | |
Full time employees 196 | |||
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinical stage for the treatment of AD; APG990, an SQ extended half-life mAb for the treatment of AD; APG333, a human mAb against thymic stromal lymphopoietin for the treatment of asthma and COPD; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.